Trial document

drksid header


Trial Description

start of 1:1-Block title


Connectivity changes as a pathological link between striatal and cortical metabolism in subtypes of patients with Parkinson's disease. A multimodal longitudinal study.

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

KFO 219 TP 10

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial


end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

Clinical subtypes of patients with Parkinson’s Disease show differences in disease progress. This mismatch points to differences in the cause of the disease. By a combination of different imaging techniques ([18F]FDG-PET, [18F]F-DOPA-PET, fMRI) in the same patient we aim to highlight these differences. PET is based on a radioactive tracer, whereas magnetic fields are used to assemble an MRI. Additionally we obtain blood samples in order to define genetic (genomics) and metabolomic (metabolomics) changes. We plan to include 65 patients with Parkinson’s Disease and 20 healthy controls. By analysing specific clusters of functionally correlated brain regions in relation to clinical progress we aim to define various subtypes of PD. By the comparison of data at baseline and 2-year-follow up we are able to analyse the time course and gain information about disease-specific changes. Mechanisms of functional compensation are to be demonstrated. The aim of identifying specific subtypes of PD by using different imaging patterns possibly has a high predictive value in relation to diagnosing Parkinson’s disease and its progress.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

- Identification of clinic, genetic, metabolomic and imaging clusters to identify subtypes in PD.
- Analysis of connections between the dopaminergic deficit, changes in functional connectivity and neuronal cortical dysfunction within subtypes.
- Identification of functional compensatory strategies.
- Implimentation of imaging techniques as a potential biomarker in clinical prediction.

end of 1:1-Block scientific synopsis
start of 1:1-Block forwarded Data

Do you plan to share individual participant data with other researchers?


end of 1:1-Block forwarded Data
start of 1:1-Block forwarded Data Content

Description IPD sharing plan:


end of 1:1-Block forwarded Data Content
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00005388
  •   2013/11/08
  •   [---]*
  •   yes
  •   Approved
  •   12-265, Ethik-Kommission der Medizinischen Fakultät der Universität zu Köln
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  • [---]*
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   G20 -  Parkinson's disease
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   65 Patients with Parkinson's Disease at baseline and 2-year-follow-up, samples of blood, urine and saliva, FDG-PET, F-DOPA-PET, resting state MRI, PANDA, MMST, BDI II, FOG-Q, NMS Scale, PDQ-39, PD Sleep Scale, UPDRS III OFF+ON
  •   20 healthy subjects at baseline, FDG-PET, F-DOPA-PET, resting state MRI
end of 1:N-Block interventions
start of 1:1-Block design


  •   Non-interventional
  •   Other
  •   Non-randomized controlled trial
  •   Open (masking not used)
  •   [---]*
  •   Other
  •   Basic research/physiological study
  •   Other
  •   N/A
  •   N/A
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

Identification and presentation of genetic and metabolomic changes and significantly changed connectivity in cerebral networks, which differ in between subtypes of parkinsons disease. We compare imaging data ([18F]FDG-PET,[18F]Dopa-PET,rsMRT) and clinical data of patients and healthy controls at baseline and of patients at baseline and 2-year-follow-up.

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome


end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • University Medical Center 
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment


  •   Actual
  •   2014/06/03
  •   85
  •   Monocenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   55   Years
  •   80   Years
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

Patients with PD: A diagnosis of Parkinson's Disease meeting the British Brain Bank Criterias; Hoehn & Yahr I-II; A tolerable withdraw of 12 hours of non retarded dopaminergic medication or of 72 hours of retarded medication, respectivly; Age 55 - 80 y; Good command of german; Written informed consent
Healthy controls: Age > 55 y; Written informed consent

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

Patients with PD: Existence of a disease which affect the cognition; Depression (BDI > 20 points); Dementia (PANDA < 14 points), Imcompliance; Containdications for MRI: cardiac pacemaker, artificial cardiac valve, internal metalic objects, pregnancy, during the period of lactation, claustrophobia, adipositas (BMI > 30)
Healthy controls: Neurological diseases; treatment with drugs affecting the CNS, which cannot be withdrawed at least 12 hours before testing; Containdications for MRI: cardiac pacemaker, artificial cardiac valve, internal metalic objects, pregnancy, during the period of lactation, claustrophobia, adipositas (BMI > 30)

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses


end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Deutsche Forschungsgemeinschaft
    • Kennedyallee 40
    • 53175  Bonn
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state


  •   Recruiting ongoing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.